Fatores associados para potenciais interações medicamentosas clinicamente significantes em terapia intensiva adulto
DOI:
https://doi.org/10.11606/issn.2176-7262.v53i4p379-388Palabras clave:
Interações de Medicamentos, Eventos Adversos , Unidade de Terapia Intensiva, Cuidados Críticos, Segurança do PacienteResumen
Modelo do estudo: Estudo transversal. Objetivo: caracterizar as interações medicamentosas potenciais (IMp) maiores e contraindicadas em terapia intensiva adulto e determinar sua prevalência, medicamentos e fatores associados à exposição dessas interações. Métodos: a amostra foi composta por 309 pacientes internados em uma unidade de terapia intensiva adulto de um hospital da Região Centro-Oeste de Minas Gerais, Brasil. Os dados demográficos-clínicos e perfil medicamentoso foram coletados, prospectivamente. As IMp foram caracterizadas pela base Micromedex 2.0 quanto à gravidade, prevalência e implicação clínica. Realizaram-se análises descritivas para as variáveis qualitativas e contínuas. Modelos Lineares Generalizados com distribuição Gama e Poisson foram utilizados para avaliar a relação entre um conjunto de variáveis independentes e a prevalência de IMp maiores e contraindicadas (p<0.05). Resultados: Um total de 81,8% (n=251) foi exposto a, no mínimo, uma IMp maior ou contraindicada. Mais de um terço (37,4%) destes participantes foram expostos a seis ou mais IMp. Medicamentos com ação no sistema nervoso colaboraram para maior probabilidade de IMp maiores e/ou contraindicadas. Pessoas idosas (p=0,006), do sexo masculino (p=0,028) e polimedicadas (<0,001) tiveram maior probabilidade de serem expostas ao menos a uma IMp maior ou contraindicada. Conclusão: Interações medicamentosas potenciais maiores e contraindicadas apresentaram alta frequência. Pessoas idosas, do sexo masculino e polimedicadas foram mais expostas às IMp maiores e/ou contraindicadas. É importante que profissionais da saúde conheçam os riscos e potenciais eventos adversos relacionados às IMp maiores e contraindicadas, para que sejam implementadas medidas para promoção da segurança do paciente.
Descargas
Referencias
Uijtendaal E, Van Harssel LLM, Hugenholtz GWK, Kuck EM, Zwart-Van Rijkom JEF, Cremer OL, et al. Analysis of potential drug-drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34(3):213–9.
Hennessy S, Leonard C, Gagne JJ, Flory JH, Han X, Brensinger CM, et al. Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions. Clin Pharmacol Ther. 2016;99(1):92–100.
Guthrie B, Makubate B, Hernandez-Santiago V, Dreishculte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74.
Askari M, Eslami S, Louws M, Wierenga PC, Dongelmans DA, Kuiper RA, et al. Frequency and nature of drug-drug interactions in the intensive care unit. Pharmacoepidemiol Drug Saf. 2013;22(4):430–7.
Secoli SR, Figueras A, Lebrao ML, de Lima FD, Santos JLF. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging. 2010;27(9):759–70.
Fitzmaurice MG, Wong A, Akerberg H, Avramovska S, Smithburger PL, Buckley MS, et al. Evaluation of Potential Drug–Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. Drug Saf. 2019;42(9):1035–44.
Cortes ALB, Silvino ZR, Santos FBM, Pereira JAC, Tavares GS. Drug Interactions Prevalence Involving High-Surveillance Drugs: a Cross-Sectional Study. Rev Min Enferm. 2019;23:e-1226.
Reis AMM, Cassiani SH de B. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics. 2011;66(1):9–15.
Carvalho REFL, Reis AMM, Faria LMP, Azevedo Zago KS, Cassiani SHB. Prevalence of drug interactions in intensive care units in Brazil. Acta Paul Enferm. 2013;26(2):150–7.
Pessoa T de L, Clemente Junior WS, Costa TX da, Bezerra PK do V, Martins RR. Drug interactions in maternal intensive care: prevalence, risk factors, and potential risk medications. Einstein (Sao Paulo). 2019;17(3):1–7.
Janković SM, Pejčić A V., Milosavljević MN, Opančina VD, Pešić N V., Nedeljković TT, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care. 2018;43:1–6.
Rodrigues AT, Stahlschmidt R, Granja S, Pilger D, Falcão ALE, Mazzola PG. Prevalence of potential drug-drug interactions in the intensive care unit of a Brazilian teaching hospital. Brazilian J Pharm Sci. 2017;53(1):e16109.
Iyer S, Wagh BR, Godbole DD, Deshmukh SS, Deshpande PR. Identification and Assessment of Potential Drug–Drug Interactions in Intensive Care Unit Patients. Indian J Crit Care Med. 2019;23(4):170–4.
Rodrigues AT, Stahlschmidt R, Granja S, Falcão ALE, Moriel P, Mazzola PG. Clinical relevancy and risks of potential drug-drug interactions in intensive therapy. Saudi Pharm J. 2015;23(4):366–70.
Łój P, Olender A, Ślęzak W, Krzych ŁJ. Pharmacokinetic drug-drug interactions in the intensive care unit — single-centre experience and literature review. Anaesthesiol Intensive Ther. 2017;49(4):259–67.
Shakeel F, Khan JA, Aamir M. Relationship of factors affecting clinically important drug interactions and their significance in surgical intensive care units in Pakistan. Lat Am J Pharm. 2018;37(4):643–50.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9.
Micromedex® Healthcare Series. Greenwood Village (US): Thomson Reuters (Healthcare) [Internet]. [cited 2019 Nov 5]. Available from: https://www-micromedexsolutions-com.ez32.periodicos.capes.gov.br
World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2019 [Internet]. [cited 2019 Jan 24]. Available from: https://www.whocc.no/atc_ddd_index/
Farzanegan B, Alehashem M, Bastani M, Baniasadi S. Potential drug-drug interactions in cardiothoracic intensive care unit of a pulmonary teaching hospital. J Clin Pharmacol. 2015;55(2):132–6.
Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ, Mirski MA. Antiepileptic drugs in critically ill patients. Crit Care. 2018;22(1):153.
Wang H, Wang C, Wang Y, Tong H, Feng Y, Li M, et al. Sedative drugs used for mechanically ventilated patients in intensive care units: a systematic review and network meta-analysis. Curr Med Res Opin. 2019;35(3):435–46.
Panahi Y, Dehcheshmeh HS, Mojtahedzadeh M, Joneidi-Jafari N, Johnston TP, Sahebkar A. Analgesic and sedative agents used in the intensive care unit: A review. J Cell Biochem. 2018;119(11):8684–93.
Instituto para Práticas Seguras no Uso de Medicamentos. Medicamentos potencialmente perigosos de uso hospitalar - lista atualizada 2019. Vol. 8, Boletim ISMP Brasil. 2019. p. 1–9.
Reis MAS, Gabriel CS, Zanetti ACB, Bernardes A, Laus AM, Pereira LRL. Potentially hazardous drugs: Identification of risks and error prevention barriers in intensive care. Texto e Context Enferm. 2018;27(2):e5710016.
Reichheld AM, Hills-Evans K, Sheehan JK, Tocci NX, Tandon M, Hsu D, et al. A national survey of approaches to manage the ICU patient with opioid use disorder. J Crit Care. 2019;54:42–7.
Andrade S, Bartels DB, Lange R, Sandford L, Gurwitz J. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther. 2016;41(5):459–77.
Kötter T, Da Costa BR, Fässler M, Blozik E, Linde K, Jüni P, et al. Metamizole-associated adverse events: A systematic review and meta-analysis. PLoS One. 2015;10(4):e0122918.
Scrignoli CP, Teixeira VCMC, Leal DCP. Drug interactions among the most prescribed drugs in adult intensive care unit. Brazilian J Hosp Pharm Heal Serv. 2016;7(2):26–30.
Currow DC, Vella-Brincat J, Fazekas B, Clark K, Doogue M, Rowett D. Pharmacovigilance in hospice/palliative care: Rapid report of net clinical effect of metoclopramide. J Palliat Med. 2012;15(10):1071–5.
Simpson PM, Bendall JC, Middleton PM. Review article: Prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: A systematic review and meta-analysis of randomized controlled trials. Emerg Med Australas. 2011;23(4):452–7.
Marquet K, Claes N, De Troy E, Kox G, Droogmans M, Vleugels A. A multicenter record review of in-hospital adverse drug events requiring a higher level of care. Acta Clin Belgica Int J Clin Lab Med. 2017;72(3):156–62.
Phansalkar S, Desai A, Choksi A, Yoshida E, Doole J, Czochanski M, et al. Criteria for assessing high-priority drug-drug interactions for clinical decision support in electronic health records. BMC Med Inform Decis Mak. 2013;13:65.
Paterno MD, Maviglia SM, Gorman PN, Seger DL, Yoshida E, Seger AC, et al. Tiering Drug-Drug Interaction Alerts by Severity Increases Compliance Rates. J Am Med Informatics Assoc. 2009;16:40–6.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2020 Juliano Teixeira Moraes, Juliana Moreira Maia, Olívia Maria Trindade, Luiz Alberto Oliveira, Cristina Sanches, Danilo Donizetti Trevisan
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.